Overview

Belatacept in De Novo Heart Transplantation

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Belatacept is safe to give to adult heart transplant recipients. Belatacept (NULOJIX) is an anti-rejection medication that is available through a prescription from a doctor. In this research study, belatacept is being used in an investigational manner (not for the purpose that it is approved for).
Phase:
Phase 2
Details
Lead Sponsor:
Marlena V. Habal
Collaborator:
Bristol-Myers Squibb
Treatments:
Abatacept
Mycophenolic Acid
Tacrolimus